Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
4D Pharma Plc ADR
(NQ:
LBPS
)
N/A
UNCHANGED
Last Price
Updated: 9:38 AM EDT, Jun 24, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 4D Pharma Plc ADR
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq
June 28, 2022
From
4D pharma plc
Via
Business Wire
Update on Suspension of Trading
June 24, 2022
From
4D pharma
Via
Business Wire
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022
From
4D pharma plc
Via
Business Wire
4D pharma to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022
From
4D pharma
Via
Business Wire
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
May 17, 2022
From
4D pharma
Via
Business Wire
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
March 31, 2022
From
4D pharma plc
Via
Business Wire
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
March 24, 2022
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...
Via
FinancialNewsMedia
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
March 23, 2022
From
4D pharma
Via
Business Wire
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
February 23, 2022
From
4D pharma
Via
Business Wire
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease
February 22, 2022
From
4D pharma plc
Via
Business Wire
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma
January 27, 2022
From
4D pharma
Via
Business Wire
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004
January 20, 2022
From
4D pharma plc
Via
Business Wire
4D pharma to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022
From
4D pharma plc
Via
Business Wire
4D pharma appoints John Doyle as Chief Financial Officer
January 03, 2022
From
4D pharma plc
Via
Business Wire
4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma
December 13, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021
December 09, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Participate in Jefferies London Healthcare Conference
November 11, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12, 2021
From
4D pharma
Via
Business Wire
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
September 15, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Participate in Upcoming Virtual Investor Conferences in September
September 09, 2021
From
4D pharma
Via
Business Wire
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
August 02, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Announces $30 Million Credit Facility with Oxford Finance
July 29, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Announces Passing of Chief Financial Officer John Beck
July 26, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
July 06, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
June 29, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Present at the Microbiome Movement Drug Development Summit
June 22, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
June 04, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
May 24, 2021
From
4D pharma plc
Via
Business Wire
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
May 17, 2021
From
4D pharma plc
Via
Business Wire
4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board
April 19, 2021
From
4D pharma plc
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.